“…Morris et al [10] reported a post-VNS implantation seizure reduction of approximately 50% in 36.8% of patients at year 1, in 43.2% at year 2, and in 42.7% at year 3 after VNS. VNS is also an effective and well-tolerated treatment for patients with Lennox-Gastaut syndrome (LGS), Dravet syndrome, and epilepsy with myoclonic-astatic seizures, and other kind of epileptic encephalopathy (Table 1) [11], [12], [13], [14], [15], [16], [17], [18]. The initial parameters were set at an output current of 0.25 mA, a signal frequency of 30 Hz, a pulse width of 250–500 ms, stimulation “on”-time 30 s, and stimulation “off”-time 300 s, with the output current generally increased to 2–3 mA as tolerated [4].…”